Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Selinexor in High Risk Hematologic Malignancies
NCT03955783Phase 1Completed
- Start
- Jun 2019
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax and selinexor in diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL). Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
venetoclaxselinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03955783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955783.